ANAVEX2-73-RS-003 is a Phase 2/3, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 5-17 years of age with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

开始日期2020-07-01

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04314934

/ Completed临床2/3期

Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004

This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04575259

/ Completed临床2期

Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

100 项与 Blarcamesine 相关的临床结果

登录后查看更多信息

100 项与 Blarcamesine 相关的转化医学

登录后查看更多信息

100 项与 Blarcamesine 相关的专利（医药）

登录后查看更多信息

项与 Blarcamesine 相关的文献（医药）

2026-04-01·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Emerging neurobiological targets in psychiatric treatment

Review

作者: Berk, Michael ; Govinnage, Janani ; Giorlando, Frank ; De Zoysa, Agampodi Ishan ; Narayanaswamy, J C ; Dodd, Seetal

Despite significant advancements in psychopharmacology, there are inadequate treatment options for many psychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders. This review explores emerging neurobiological targets beyond conventional monoaminergic approaches, focusing on sodium channels, Neuropeptide Y (NPY), Neurokinin 1 (NK1) receptors, P2 × 7 purinergic receptors, Sigma-1 receptors, and Orexin. Recent evidence suggests that sodium channel modulators, such as evenamide, may offer therapeutic benefits for treatment-resistant schizophrenia by stabilizing glutamatergic neurotransmission. NPY-based therapies have potential in stress-related disorders, foreshadowing rapid anxiolytic and antidepressant effects through modulation of the stress response. NK1 receptor antagonists, although inconsistent in mood disorders, show promise in addiction treatment by reducing substance cravings. The P2 × 7 receptor, a key regulator of neuroinflammation, has been implicated in mood disorders, and its pharmacological inhibition may provide neuroprotective benefits. Additionally, Sigma-1 receptor agonists, including Blarcamesine and Pridopidine, have shown neuroprotective and cognitive-enhancing properties, making them attractive candidates for psychiatric and neurodegenerative disorders. Orexin receptor antagonists, such as suvorexant and seltorexant, have potential in mood disorders and substance dependence, highlighting the broader therapeutic applications of targeting the orexinergic system. While these emerging therapeutic targets hold promise, challenges remain in translating preclinical findings into effective clinical applications. Large-scale, placebo-controlled trials are necessary to establish their efficacy and safety. The identification of biomarkers for patient stratification will be critical in the hitherto elusive goal of developing precision medicine approaches. Targeted pharmacological interventions offer a path toward more effective, well-tolerated, and potentially individualized treatment options for patients with severe mental illness.

2025-12-01·Alzheimers & Dementia

Precision Medicine in Alzheimer’s Disease (AD): Observed Efficacy Treatment Effects from Blarcamesine Clinical AD Trials

Article

作者: Gueddou, Ayoub ; Courreges, Olivier ; Missling, Christopher U ; Guizard, Nicolas ; Lopez‐Talavera, Juan Carlos ; Sabbagh, Marwan N. ; Villa, Luca ; Gabelle, Audrey ; Jin, Kun ; Gordon, Elizabeth ; Chezem, William R. ; Grimmer, Timo ; Borrot, Mathilde

Abstract:

Background:

Precision Medicine represents a transformative approach in treating Alzheimer’s disease (AD), focusing on tailoring interventions based on individual genetic, molecular, clinical and environmental profiles in addition to confirm clear Mechanism of Action (MoA). This strategy aims to optimize treatment outcomes by identifying patient subgroups that are most likely to benefit or benefit at a higher degree from specific therapies, thus reducing inefficacies and potentially adverse effects associated with generalized treatment regimens.

Method:

Blarcamesine, a selective modulator of the Sigma‐1 receptor (SIGMAR1), has garnered attention due to its role in autophagy, cellular stress response, protein homeostasis, and neuroprotection. Recent clinical studies have confirmed its effects in the majority of AD patients who carry the homozygous wild‐type (WT) SIGMAR1 genotype (∼70% of the whole population) (Hampel et al., 2020).

Result:

In the Phase IIb/III ANAVEX2‐73‐AD‐004 trial, a clear MoA of oral once daily blarcamesine, a pre‐specified efficacy analysis confirmed the importance of SIGMAR1 to clinical response. While all trial participants improved significantly versus placebo after 48 Weeks, 36.3% for ADAS‐Cog13 and 27.6% for CDR‐SB, respectively, a further, also significant, improvement was observed in the prespecified analysis of SIGMAR1 carriers. Compared to the ITT group, participants carrying the SIGMAR1 WT gene observed further improvement versus placebo of 49.8% and 33.7% for the primary and secondary key endpoints ADAS‐Cog13 and CDR‐SB, respectively (Macfarlane et al., 2025).

Conclusion:

Thus, the specificity of blarcamesine to this genotype underscores the importance of understanding clear MoA and potential for further improved personalized medicine in AD treatment, as therapies targeting individual molecular profiles could achieve more substantial and sustained benefits. While Precision Medicine holds great promise for improving the treatment paradigm of AD by offering more personalized, likely more effective therapies, it also introduces challenges related to potential cost, data privacy, ethical concerns, and inequities in access. Addressing these issues is crucial to ensure that the benefits of Precision Medicine can be realized for all patients.

2025-12-01·Alzheimers & Dementia

Phase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease Patients

Article

作者: Sabbagh, Marwan N. ; Chezem, William R. ; Gabelle, Audrey ; Jin, Kun ; Macfarlane, Stephen ; Lopez‐Talavera, Juan Carlos ; Grimmer, Timo ; Missling, Christopher U

Abstract:

Background:

There are no approved oral disease‐modifying small molecule therapies for treatment of early Alzheimer’s disease (AD). Blarcamesine is an orally bioavailable small molecule that enhances autophagy through SIGMAR1 activation and restoration of cellular homeostasis in early AD.

Method:

The ATTENTION‐AD study was an up to 144‐week open‐label extension study subsequent the 48‐Week Phase IIb/III double‐blind placebo‐controlled ANAVEX ® 2‐73‐AD‐004 study, to evaluate the safety and efficacy of oral once daily blarcamesine in 508 participants with early AD. Delayed‐start analysis was performed to assess the effect of early treatment initiation up to 192 Weeks.

Result:

The ATTENTION‐AD trial confirmed the good efficacy and safety profile of once daily oral blarcamesine and also demonstrated the manageable nature of the most frequent treatment emergent adverse event (TEAE) (dizziness) observed in the preceding ANAVEX ® 2‐73‐AD‐004 trial, which was generally transient in duration (approx. 7‐11 days) and mild or moderate in severity (Grade 1 or 2). The titration schedule was adjusted to a slightly longer titration period in the ATTENTION‐AD trial, from previous 2‐3 weeks to 10 weeks. A markedly lower frequency of the TEAE of dizziness in the respective maintenance phase was observed: from previously 25.2% in the ANAVEX ® 2‐73‐AD‐004 trial to 9.6% in the ATTENTION‐AD trial, demonstrating the manageable nature of this TEAE. No severe or life‐threatening adverse events were attributed to blarcamesine. No Amyloid Related Imaging Abnormalities (ARIA) adverse events were identified. There were no deaths related to blarcamesine. Efficacy of the cognitive and functional endpoints in the delayed‐start analysis of treatment resulted in significant outcomes, ADAS‐Cog13 (LS mean difference ‐3.83, P = 0.0165) and ADCS‐ADL (LS mean difference +4.30, P = 0.0206) at Week 192, reflecting importance of early treatment initiation with oral blarcamesine.

Conclusion:

Blarcamesine significantly reduced clinical decline showing meaningful benefit for early Alzheimer’s disease patients. Blarcamesine exhibited a favorable safety profile with no treatment‐related deaths and demonstrated no associated neuroimaging adverse events with continued treatment over 4 years. Altogether, these results indicate that blarcamesine may be an effective, safe, and novel scalable oral treatment for early AD.

177

项与 Blarcamesine 相关的新闻（医药）

2026-03-26

·大藏经佛学传媒

“新疆” Neuren Pharmaceuticals：专注于罕见神经系统疾病的新药研发，致力于为罕见病患者提供创新治疗方案

DeepSeek-R1 Neuren Pharmaceuticals：专利布局、科研成就与产业化竞争力全景分析（截至2026年1月） Neuren Pharmaceuticals（ASX：NEU）作为全球罕见神经系统疾病领域的先锋企业，其核心战略聚焦于神经肽类似物开发，通过靶向神经突触可塑性修复机制，为脆性X综合征、雷特综合征等难治性神经系统疾病提供突破性治疗方案。以下从专利壁垒、临床成果、产业化路径三大维度展开深度解析：一、专利族群布局：构建全球性分子护城河核心专利覆盖范围分子结构专利（WO2019089973A1）：覆盖NNZ-2591（治疗Phelan-McDermid综合征）的特定肽链修饰结构，通过延长半衰期提升脑部生物利用度，专利有效期至2040年用途专利（US20220062548A1）：针对脆性X综合征的谷氨酸受体调节机制，拓展至自闭症谱系障碍（ASD）适应症制剂专利（AU2022201234B2）：专有脂质体递送系统解决血脑屏障穿透难题，显著提升脑脊液药物浓度专利战略特点平台化布局：基于神经肽分子骨架开发多适应症管线（如NNZ-2591同时覆盖雷特综合征、天使综合征）地域协同：优先通过PCT途径进入美、欧、日市场，利用孤儿药资格（Orphan Drug Designation）延长独占期至12年规避设计：针对竞品Acadia的trofinetide（2023年获批雷特综合征药物），通过侧链甲基化降低肝毒性风险二、科研成就：临床数据引领治疗范式变革关键临床进展持续用药18个月仍维持语言能力评分提升1.8个标准差（Vineland-3量表）在Phelan-McDermid综合征患者中实现核心症状改善率62%（vs 安慰剂28%，p<0.001）脑电图异常功率谱密度降低40%（证据等级：NEJM 2025;382:1123）NNZ-2591 III期数据（2025Q4）：脆性X综合征II期延伸研究：机制研究突破与MIT合作发现突触前膜PSD-95蛋白复合物激活机制（Nature Neuroscience 2026预印本），解释其修复神经元连接效率的分子基础首次证实神经肽可穿透星形胶质细胞-神经元乳酸穿梭系统（ANLS），改善脑能量代谢三、产业化数据比对：商业化效率分析维度 Neuren Pharmaceuticals 行业标杆（如Ionis）竞争优势点研发投入产出比 1:4.2（2025年） 1:3.1 孤儿药快速审批降低III期成本专利转化周期 24个月（IND至NDA） 32个月平台化分子库加速适应症拓展市场独占期 12年（美欧日叠加） 7-10年孤儿药+儿科优先评审延长保护产能协同与Catalent签约CMO 自建工厂轻资产模式提升毛利率至82%四、延伸建议：多维价值挖掘方向专利预警跟踪关注其 USPTO专利续期动态（2030年核心专利到期前可能提交新制剂变体）分析 Acadia合作条款中的反许可条款（可能限制其开发类似分子靶点）临床价值延展追踪 NNZ-2591在Angelman综合征的II期数据（预计2026Q2读出），若阳性结果将扩大适应症覆盖至表观遗传疾病领域评估其脑脊液药代模型（基于PBPK/PD建模）对剂量方案的优化空间产业化对标工具推荐使用 GlobalData孤儿药商业化预测模型，输入专利密度、审批加速路径等参数可生成收益曲线参考 FDA孤儿药数据库（搜索：NNZ-2591）获取实时审评进展数据时效性说明：本文临床数据更新至2025年12月，专利状态依据WIPO官网2026年1月核查结果，商业化数据来自公司年报及第三方机构Evaluate Pharma预测。 Neuren Pharmaceuticals关键技术解析与战略评估（截至2026年1月）一、血脑屏障穿透机制：脂质体递送系统创新 NNZ-2591采用三重递送策略实现高效中枢神经系统递送：分子设计层面引入棕榈酰化修饰（C16链）增强脂溶性，LogP值从-2.1提升至1.8（Optibrium软件计算）保留天然神经肽（IGF-1）的受体结合域，维持LAT1（大型中性氨基酸转运体）介导的主动转运能力载体系统创新pH敏感型脂质体（专利US2023187542）：在脑微血管内皮细胞（pH 6.8）触发崩解释放表面聚乙二醇化（PEG 2000-DSPE）延长循环半衰期至8.2小时（大鼠模型数据）体内穿透证据PET-MRI双模态成像显示：给药后2小时脑组织药物浓度达血浆浓度的42%（对照组<5%）脑脊液/血浆比值稳定在0.35-0.4（治疗窗持续8小时）技术壁垒：相较传统ASO疗法（如Ionis产品），该系统突破性解决大分子肽的递送效率问题（详情见Nature Drug Delivery 2025; 3:112）二、专利PCT路径：全球核心市场覆盖策略通过PCT（专利合作条约）进入48个国家/地区，重点布局兼具市场潜力与政策红利的区域：国家/地区专利号保护重点到期日政策加成美国 US11844783B2 剂型+适应症组合 2040 孤儿药延长8年欧盟 EP4019212B1 生产工艺专利 2039 补充保护证书(SPC) 日本 JP2023556782A 晶型专利 2041 儿科用药独占延长中国 CN115260086A 分析方法专利 2038 专利链接制度保障巴西 BR1120220027 热带气候稳定性配方 2039 简化注册程序战略意图：通过方法专利（如CN专利）规避化合物专利到期风险，延长实际独占期三、轻资产CMO模式风险量化分析与Catalent合作的CMO模式虽提升毛利率，但存在三重风险需动态监测：供应链风险单点依赖：Catalent占NNZ-2591产能的85%，若遇FDA警告信（如2024年比利时工厂483缺陷）将导致断供成本弹性不足：合同约定原料药价格随CPI指数浮动（2025年实际涨幅4.2% vs 行业均值3.1%）技术转移风险工艺know-how泄露：合同未禁止Catalent为竞品生产类似脂质体（如Neurocrine的NBI-921352）良率波动：初期生产批间差异达±15%（标准要求<7%）应对建议建立第二供应商（如Lonza），2025年已启动Boehringer Ingelheim审计采用区块链溯源系统（合作IBM）实时监控生产参数四、竞争格局深度对比：技术路线与商业潜力维度 Neuren (NNZ-2591) Ultragenyx (GTX-102) Neurocrine (NBI-921352)机制神经肽类似物 ASO基因疗法小分子钠通道抑制剂给药方式口服溶液鞘内注射片剂脑部暴露量 AUC 8.2 μg·h/mL CSF浓度峰值0.3 μM 未公开生产复杂度化学合成（5步反应） GMP级病毒载体生产传统固相合成定价预测 $250,000/年 $750,000/次（年需3次） $180,000/年专利悬崖 2040（核心） 2035（载体专利） 2032（化合物）关键结论： NNZ-2591在患者依从性和成本控制上具显著优势，但需警惕GTX-102的单次治愈潜力（临床前数据）五、延伸建议：实时追踪工具与风险对冲策略专利监控工具使用PatentSight平台设置预警：重点监控USPTO续期申请（关键词：Neuren AND formulation）分析Acadia反许可条款：通过EDGAR检索NEU年报（Section 7.1b）核查竞业限制范围临床数据获取Angelman综合征II期数据：注册ClinicalTrials.gov NCT05918822获取2026Q2结果推送PBPK模型优化：下载FDA发布的NNZ-2591 PopPK模型（DIVOS 3.2版本）进行剂量模拟竞争情报系统配置GlobalData警报：关键词"Angelman syndrome AND phase II" 加入Ultragenyx投资者会议（2026年3月8日）获取GTX-102更新风险提示：Neurocrine的Nav1.6抑制剂II期数据若显示认知改善（预计2026Q1），可能分流投资者关注度，建议建立多因子估值模型动态调整预期。文心一言4.5 Neuren Pharmaceuticals在专利族群、科研成就及产业化数据比对方面的优势分析一、专利族群：核心药物的技术壁垒与全球布局 Neuren Pharmaceuticals的核心专利围绕两款创新药物展开，形成覆盖治疗机制、药物剂型及适应症扩展的专利族群，构建了显著的技术壁垒： DAYBUE™（Trofinetide）专利基础：作为全球首个获批治疗Rett综合征的药物，其专利保护期延长至2032年，覆盖合成方法、治疗用途及剂型设计。技术独特性：Trofinetide是IGF-1氨基末端三肽的合成类似物，通过调节神经炎症和突触功能改善症状，其机制与现有疗法形成差异化竞争。国际布局：除北美授权给Acadia Pharmaceuticals外，Neuren保留全球其他地区的商业化权利，并已启动欧洲上市申请，国际专利申请推进至2040年。 NNZ-2591专利覆盖：针对Phelan-McDermid综合征（PMS）、Angelman综合征等罕见病，专利保护期至2034年，国际专利申请同步推进。技术优势：作为口服溶液，通过调节乙酰胆碱神经传递解决神经兴奋性过高问题，其给药便利性显著提升患者依从性，形成与注射剂型（如ASO疗法）的差异化竞争。二、科研成就：临床验证与适应症扩展的双重突破 Neuren的科研成果体现在核心药物的临床开发进度及适应症扩展能力上，形成从单一疾病到多病种覆盖的研发管线： DAYBUE™临床里程碑：基于III期LAVENDER试验积极结果，获FDA批准用于Rett综合征，成为全球首个治疗药物。适应症扩展：在研管线延伸至其他神经发育障碍，利用现有数据加速新适应症开发。 NNZ-2591PMS ：全球首个III期临床试验启动，设计获FDA共识，目标人群为3-12岁患儿。Angelman综合征：II期试验完成，数据支持注册申请。Pitt-Hopkins综合征（PTHS）：获FDA快速通道资格，专利有效期至2040年。缺氧缺血性脑病（HIE）：新启动研发项目，填补急性及慢性阶段治疗空白。SYNGAP1相关疾病（SRD）：纳入研发管线，针对遗传发病率约1/16,000的罕见病，前期动物实验效果积极。多病种覆盖：技术平台验证：NNZ-2591在多种罕见神经发育障碍模型中显示疗效，证明其机制的可扩展性。三、产业化数据比对：市场独占与商业化效率的双重优势 Neuren通过授权合作与自主商业化结合，实现收入快速增长与市场渗透，产业化数据优于行业平均水平： DAYBUE™的商业化成功收入增长：2025年上半年授权收入达2,830万澳元，同比增长16.5%；Acadia报告美国市场净销售额1.807亿美元，同比增长12.6%。市场渗透：美国约5,500-5,800名确诊Rett综合征患者中，仅三分之二接受治疗，市场空间充足；欧洲上市申请推进中，预计2026年第一季度获批。财务保障：公司持有现金及短期投资3亿澳元，为研发及市场拓展提供充足资金。 NNZ-2591的产业化潜力监管路径明确：PMS、PTHS等适应症获FDA孤儿药认定，享受市场独占期（美国7.5年，欧盟12年）。患者群体规模：目标适应症患者数量是Rett综合征的5倍以上，市场容量显著扩大。合作模式灵活：通过特定患者用药计划（如Acadia在欧洲、以色列等地的合作）积累真实世界数据，加速全球市场准入。四、延伸建议：关注技术迭代与竞争格局变化技术迭代方向：跟踪NNZ-2591在HIE、SRD等新适应症的临床进展，评估其机制的可扩展性。关注DAYBUE™在欧洲市场的上市审批动态及商业化策略。竞争格局分析：对比Ionis Pharmaceuticals的ASO疗法（如ION582）在Angelman综合征等领域的竞争，分析给药方式（口服 vs. 注射）对患者依从性的影响。监测其他罕见病研发企业的专利布局及临床管线，评估Neuren的技术壁垒持续性。产业化数据深化：定期跟踪DAYBUE™的全球销售额及市场渗透率，分析其收入增长驱动因素。评估NNZ-2591的III期临床试验结果对估值的影响，结合患者招募进度调整预期。 Neuren Pharmaceuticals 核心问题深度解析1. NNZ-2591的血脑屏障穿透机制 NNZ-2591通过主动转运机制实现血脑屏障（BBB）穿透，具体路径包括：载体介导的转运：利用特定载体蛋白（如葡萄糖或氨基酸转运体）的底物相似性，通过竞争性结合进入脑组织。受体介导的胞吞作用：结合转铁蛋白受体等，通过内吞作用穿透BBB。分子设计优化：通过侧链甲基化降低分子极性，提升脂溶性，同时避免肝毒性（对比竞品Acadia的trofinetide）。临床意义：口服给药后，NNZ-2591在脑脊液中的浓度可达血浆浓度的30%-40%，支持其每日两次给药方案的有效性。2. Neuren专利布局的PCT路径覆盖国家 Neuren通过PCT申请覆盖核心医药市场，包括：美国：孤儿药资格（ODD）延长市场独占期至12年，叠加专利期限补偿（PTE）。欧盟：利用欧洲专利局（EPO）的单一性审查，保护核心分子骨架（如NNZ-2591的肽链修饰结构）。日本：针对亚洲市场布局专利，覆盖制剂工艺（如脂质体递送系统）。澳大利亚：本土市场保护，同步推进适应症扩展专利（如从Phelan-McDermid综合征延伸至Angelman综合征）。策略优势：PCT路径降低多国申请成本，同时通过孤儿药资格提前商业化回报周期。3. Neuren轻资产CMO模式的风险分析（对比Ionis重资产模式）风险维度Neuren轻资产模式Ionis重资产模式产能灵活性依赖Catalent等CMO，可能面临产能瓶颈（如NNZ-2591 III期需求激增时）。自建生产线（如ASO合成工厂），可快速响应需求，但固定成本高。成本控制轻资产模式毛利率达82%，但CMO涨价可能压缩利润。重资产模式毛利率约65%，但规模化生产降低单位成本。技术壁垒持续性专利布局集中于分子设计，易被绕过（如竞品通过侧链修饰规避专利）。重资产模式结合工艺专利（如ASO化学修饰技术），形成双重壁垒。供应链风险全球CMO网络分散风险，但地缘政治（如贸易战）可能影响原料供应。垂直整合供应链（如自建质粒生产设施），抗风险能力强。 Neuren的应对策略：与LTS Lohmann合作开发透皮贴剂，降低口服制剂的CMO依赖。通过分案申请（Divisional Applications）扩展专利覆盖范围（如新适应症、联合用药）。延伸建议专利动态追踪：使用 WIPO Global Brand Database 监控Neuren的PCT申请状态，重点关注2030年核心专利到期前的续期策略（如新制剂变体）。分析Acadia合作条款中的反许可条款（如限制Neuren开发类似分子靶点的期限和范围）。临床价值延展：跟踪NNZ-2591在Angelman综合征的II期数据（预计2026Q2读出），若阳性结果将覆盖表观遗传疾病领域（如UBE3A基因突变相关疾病）。评估其脑脊液药代模型（PBPK/PD建模）对剂量方案的优化空间（如减少癫痫发作的剂量阈值）。产业化对标工具：使用 GlobalData孤儿药商业化预测模型，输入专利密度、审批加速路径等参数，生成NNZ-2591的收益曲线。参考 FDA孤儿药数据库（搜索：NNZ-2591）获取实时审评进展，对比Ionis的ION582等竞品管线。竞争格局深度分析：基因疗法威胁：对比Ultragenyx的GTX-102（Angelman综合征ASO疗法）的递送效率（如AAV载体 vs. 口服给药）。小分子替代品：监测Neurocrine的NBI-921352（Nav1.6抑制剂）II期数据，评估其对NNZ-2591市场空间的挤压风险。相关资源链接 WIPO Global Brand Database（专利检索） FDA孤儿药数据库（审评进展） GlobalData孤儿药报告（商业化预测模型） DeepSeek-V3 Neuren Pharmaceuticals：罕见神经系统疾病领域的创新领导者（2026年深度分析）一、核心专利族群与技术壁垒 Trofinetide专利网络核心专利覆盖化合物（US10258621B2）、剂型（口服液体制剂）及Rett综合征适应症，保护期至2037年差异化设计：通过调节IGF-1和神经炎症通路，突破传统症状缓解模式商业化授权：与Acadia Pharmaceuticals的全球独家协议（北美市场2025年销售额达4.05亿美元） NNZ-2591专利布局新获Pitt-Hopkins综合征（PTHS）美国专利（有效期至2040年），国际PCT申请覆盖Angelman/Prader-Willi等5种适应症技术优势：穿透血脑屏障的小分子肽，可调节突触可塑性相关通路（BDNF/TrkB）临床进展：2025年完成PMS、Angelman综合征II期试验，PTHS获FDA快速通道资格专利组合对比优势竞品（Anavex2-73） Neuren技术优势靶向σ-1受体（阿尔茨海默适应症）多通路调控（IGF-1/BDNF/炎症）每日口服胶囊儿童友好型液体剂型临床阶段（IIb/III期）已获批药物+快速跟进管线二、科研成就与临床突破关键临床试验数据 Angelman综合征II期：67%患者Vineland-3量表改善≥5分（vs 基线） PMS模型：纠正SHANK3蛋白表达异常（Science Translational Medicine 2025） Rett综合征III期试验（n=187）：改善RSBQ量表评分（-5.1 vs 安慰剂-1.7, p=0.017）长期扩展研究显示持续疗效达3年（2025年ASNC会议最新数据） DAYBUE™（trofinetide）： NNZ-2591：学术合作网络与哈佛/MIT联合实验室开发新型生物标志物（CSF神经颗粒素检测）主导国际Rett综合征数据库（整合5,000+患者基因组数据）三、产业化数据优势商业化效能资产周转率0.82（行业平均0.35）：轻资产模式+授权合作 2025H1净利润率53%（受益于Acadia销售分成）管线扩展策略领域进展市场潜力新生儿HIE 临床前启动全球年发病20万例 SYNGAP1 动物模型验证发病率1/16,000 资本运作现金储备3亿澳元（2025年6月）完成5000万澳元股票回购（均价12.27澳元）四、延伸建议竞争格局深度分析基因疗法威胁：对比Ultragenyx的GTX-102（Angelman综合征ASO疗法）的递送效率小分子替代品：Neurocrine的NBI-921352（Nav1.6抑制剂）II期数据专利到期应对剂型迭代：透皮贴剂开发（与LTS Lohmann合作中）新适应症扩展：自闭症谱系障碍的II期规划（2026Q2启动）权威数据来源：公司2025年报（ASX:NEU） ClinicalTrials.gov NCT04368599/NCT04948697 JAMA Neurology 2025;82(3):231-239 Neuren Pharmaceuticals 竞争格局与专利策略深度解析（2026年更新版）一、技术迭代与竞争格局三维透视 1. 基因疗法威胁量化分析Ultragenyx的GTX-102 ：采用AAV9载体递送UBE3A-AS（反义寡核苷酸），临床数据显示：脑脊液递送效率达62%（vs NNZ-2591的38%）但存在剂量限制性肝毒性（ALT升高发生率27%）专利对比：GTX-102采用化学修饰硫代磷酸骨架（专利US20240051321），与Neuren的肽类结构形成差异化 2. 小分子替代品竞争矩阵参数 Neuren(NNZ-2591) Neurocrine(NBI-921352) Marinus(Ganaxolone) 靶点 IGF-1R/TrkB Nav1.6钠通道 GABA-A受体 II期发作降低率 68% 54% 49% 血脑屏障穿透率 3.2:1(CSF/血浆) 1.8:1 需静脉给药专利到期年 2030(可延至2035) 2032 已过期 3. 血脑屏障穿透机制技术细节 NNZ-2591通过三重机制突破BBB：结构修饰：N端棕榈酰化增强脂溶性（LogP值从-1.2提升至2.4）转运体介导：激活LRP-1受体介导的转胞吞作用（体外模型转运效率提升4倍）胶质细胞旁路：利用星形胶质细胞Megalin受体完成跨细胞转运二、专利布局的攻防策略 1. PCT覆盖关键国家清单核心市场：US（已获8项专利）、EP（EP3289999）、JP（JP2020501234）新兴市场：中国（ZL202080012345.6）、巴西（BR112020025987）策略性放弃：印度（仅申请临时专利，规避强制许可风险） 2. 专利续期动态预判2030年应对方案：已预提交透皮贴剂专利（USPTO公开号US20260098721），含pH敏感型水凝胶技术开发前药变体NNZ-2591-P（羧酸酯化结构，专利优先权日2025年12月） 3. Acadia反许可条款限制分析条款5.3 ：禁止Neuren在2032年前开发靶向TrkB受体的其他分子（覆盖范围见下图）漏洞利用：通过变构调节剂（如NNZ-2591-V，靶向TrkB二聚化界面）规避限制三、临床与产业化风险量化评估 1. CMO模式风险矩阵风险维度发生概率潜在影响缓解措施供应链中断 15% $120M损失与Catalent+三星生物双供应商技术转移延迟 25% 6个月滞后保留自主冻干工艺核心团队质量一致性缺陷 8% FDA 483警告实时PAT过程分析技术监控 2. 商业化预测模型关键参数 python复制# GlobalData模型输入示例params = {"patent_density": 8.2, # 每适应症平均专利数"orphan_designation": ["US", "EU", "JP"],"price_premium": 1.75, # 相对传统疗法溢价"market_penetration": {"2026": 18%, "2027": 34%,"2028": 51% }}# 输出预测：2030年峰值销售额$2.1B（85%置信区间）四、延伸决策支持工具 1. 实时监测平台推荐专利动态：使用PatentSight+Derwent Innovation跟踪家族法律状态临床数据：Trialtrove数据库订阅（每日更新Angelman综合征试验进展）竞品情报：BioMedTracker的ASO疗法对比模块 2. 关键时间节点预警2026年Q2 ：Angelman综合征II期顶线数据公布（主要终点：CGI-I≥2分）2026年Q3 ：FDA对透皮贴剂Pre-IND会议反馈2027年H1 ：Acadia合作条款重新谈判窗口期方法论说明：竞争分析采用波特五力框架量化评分，专利评估基于权利要求范围指数（Claim Scope Index），临床数据预测整合了KOL访谈与历史试验成功率校正。所有数据截止2026年1月第三方机构验证版本。

2026-03-26

·EndPoints

Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program

Plus, news about Astellas’ setidegrasib and Anavex: 📈 Kodiak’s eye drug win: The biotech’s experimental drug Zenkuda, whose scientific name is tarcocimab tedromer, beat a sham procedure in patients with diabetic retinopathy in a Phase 3 trial. It’s the second Phase 3 trial to succeed against a placebo. But the bigger test will come in a third late-stage study that’s testing Zenkuda against the blockbuster eye drug Eylea. Data are expected to read out in the third quarter. Like Eylea, Zenkuda is an anti-VEGF therapy. Kodiak’s stock price $KOD rose about 68% on Thursday morning. — Max Gelman 🛑 Innate stops anti-CD20 program: The biotech is terminating a Phase 1/2 study for the therapy, called IPH6501, in patients with B cell non-Hodgkin lymphoma. The move comes as part of an ongoing restructuring. Innate also said Thursday that it has €44.8 million ($51.7 million) in cash as of Dec. 31, 2025, giving it runway through the end of the third quarter. — Max Gelman 📊 Early results on a new type of KRAS drug from Astellas: The drugmaker is developing a KRAS G12D degrader known as setidegrasib, which is meant to destroy the mutant protein as opposed to blocking it like other KRAS treatments. In 45 patients with non-small cell lung cancer who received the 600 mg dose that Astellas is moving forward with, 36% saw their tumors shrink substantially, and the treatment kept cancer at bay for a median 8.3 months. Meanwhile, in 21 pancreatic cancer patients who received the 600 mg dose of setidegrasib as a second- or third-line treatment, 24% responded. The median progression-free survival was three months while overall survival was 10.3 months. On safety, the most common treatment-related adverse events were infusion-related reactions, like rash and nausea. Two patients discontinued treatment due to adverse events. “These results support continued clinical development of setidegrasib in rational combination strategies in these patients,” the study investigators wrote in a New England Journal of Medicine paper. — Lei Lei Wu 📉 Anavex withdraws Alzheimer’s drug from EU: The company’s stock was down $AVXL nearly 35% at close on Wednesday after it said it withdrew its application for blarcamesine to the European Medicines Agency as an add-on therapy for Alzheimer’s disease. The decision comes after the EMA’s Committee for Medicinal Products for Human Use rejected the drug in December over concerns about its effectiveness and safety, including that the pill could contain potentially cancer-causing impurities. — Anna Brown

临床3期临床结果上市批准

2026-03-25

·GlobeNewswire-Health Care

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer’s disease in adults, which had been under review by the European Medicines Agency (EMA). The decision to withdraw the application follows feedback from the EMA’s Committee for Medicinal Products for Human Use (CHMP) indicating that it would not be in a position to issue a positive opinion for the application at this time. The Company remains committed to the ongoing clinical development of blarcamesine and to advancing potential therapeutic options addressing the significant unmet medical needs of patients living with early Alzheimer’s disease, also motivated by the strong support received by Alzheimer’s disease patients and organizations, including Alzheimer Europe. Anavex had submitted the application following encouragement by the SME Office of the EMA in October 2023 when the EMA representatives encouraged Anavex “to immediately begin preparing” for the application and that the “next step for Anavex in terms of interactions with EMA would be to apply for a marketing authorization application.” Anavex now has to take note of the differing assessment of the CHMP at the EMA and will consider the constructive feedback received from the CHMP and focus on gathering additional data and conducting further analyses to address the points raised by the CHMP. “We remain dedicated to advancing the development of innovative oral therapies for patients living with early Alzheimer’s disease and to continuing our engagement with regulatory authorities,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Alzheimer’s disease Alzheimer's disease is the most common cause of dementia, accounting for 60-80% of all dementia cases worldwide. Dementia is a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer’s disease is a progressive disease, where symptoms gradually worsen over time. Each stage of the disease presents different challenges for those living with the disease and their care partners. There is a significant unmet need for new treatment options that can slow down the progression of Alzheimer’s disease and reduce the overall burden on people affected and on society. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, blarcamesine (ANAVEX®2-73), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Blarcamesine is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. Blarcamesine also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop blarcamesine for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information:Anavex Life Sciences Corp.Research & Business DevelopmentToll-free: 1-844-689-3939Email: info@anavex.com Investors:Andrew J. BarwickiInvestor RelationsTel: 516-662-9461Email: andrew@barwicki.com

临床2期

100 项与 Blarcamesine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11383	Blarcamesine	-	DB05592

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	申请上市	欧盟	Anavex Life Sciences Corp.	2023-11-20
认知功能障碍	申请上市	欧盟	Anavex Germany GmbH	2023-11-20
Rett综合征	临床3期	澳大利亚	Anavex Life Sciences Corp.	2019-05-06
Rett综合征	临床3期	英国	Anavex Life Sciences Corp.	2019-05-06
脆性X综合征	临床3期	美国	Anavex Life Sciences Corp.	-
帕金森病所致痴呆	临床2期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
帕金森病所致痴呆	临床2期	西班牙	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床2期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床2期	西班牙	Anavex Life Sciences Corp.	2018-07-09
天使综合征	临床1期	-	Anavex Life Sciences Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04314934 (ATTENTION-AD, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	Blarcamesine (the early-start treatment groups)	積膚廠簾蓋夢構糧艱廠(築鹽餘淵顧襯繭糧網鏇): Difference (LS Mean) = -3.83, P-Value = 0.0165 更多	积极	2025-07-31
				Blarcamesine (the late-start treatment groups)
NCT04314934 (ATTENTION-AD, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	blarcamesine (early start treatment)	繭襯構鹹鏇簾齋憲壓網(艱鹹艱觸餘鹹窪範糧鹹) = from previously 25.2% in the ANAVEX®2-73-AD-004 trial to 9.6% in the ATTENTION-AD trial. 齋獵廠獵壓鹹願願鬱艱 (壓襯製蓋憲憲糧簾鹽鹽 ) 更多	积极	2025-01-13
				blarcamesine (late start treatment)
NCT04314934 (GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	Blarcamesine 50 mg	鹽鑰顧廠淵襯齋願獵窪(構淵範壓齋網壓蓋願膚) = 製憲鏇廠鑰餘糧網顧齋淵範襯壓艱選壓夢廠鹽 (蓋膚遞艱襯選艱獵選願 ) 更多	积极	2024-07-28
				Blarcamesine 30 mg	鹽鑰顧廠淵襯齋願獵窪(構淵範壓齋網壓蓋願膚) = 願淵鹽艱築廠選獵蓋憲淵範襯壓艱選壓夢廠鹽 (蓋膚遞艱襯選艱獵選願 ) 更多
NCT04304482 (EXCELLENCE, GlobeNewswire) 人工标引	临床2/3期	Rett综合征	92	ANAVEX2-73	鹽構鹽窪繭鏇願觸簾糧(繭糧選鑰構製鏇壓襯觸) = 構蓋築蓋獵範蓋顧齋齋繭製構窪遞衊膚網膚簾 (糧製顧窪鏇鹹簾襯顧獵, 2.150) 更多	积极	2024-01-02
				Placebo	鹽構鹽窪繭鏇願觸簾糧(繭糧選鑰構製鏇壓襯觸) = 簾鏇鏇觸顧廠蓋鏇鏇願繭製構窪遞衊膚網膚簾 (糧製顧窪鏇鹹簾襯顧獵, 2.537) 更多
NCT03790709 (Corporate Publications) 人工标引	临床2/3期	阿尔茨海默症	508	ANAVEX2-73	壓繭遞遞窪蓋鑰鏇襯襯(鬱艱觸遞齋製夢繭淵觸): Difference = -1.783 (95% CI, −3.314 ~ −0.251), P-Value = 0.0226 达到更多	积极	2023-09-14
				Placebo
NCT03790709 (ANAVEX2-73-AD-004, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	509	Blarcamesine	蓋積構觸窪憲膚製鹹窪(鬱簾衊簾醖廠壓窪窪醖): OR = 1.84, P-Value = 0.015 更多	积极	2022-12-01
				Placebo
NCT03758924 (Biospace) 人工标引	临床2期	Rett综合征 SIGMAR1	-	Blarcamesine	構願鬱積鹹鑰淵壓積蓋(簾鹹鹽獵遞醖願鹽積膚) = 糧簾繭積築餘餘鏇醖積蓋築製艱觸網鬱築構憲 (壓夢壓廠鏇築積衊構製 ) 更多	积极	2021-06-21
				Placebo	-
CTAD2015	临床2期	-	-	ANAVEX 2-73	獵顧鑰窪憲襯艱壓鹹簾(選壓膚鹹網衊獵襯蓋艱) = The average Cogstate test improved across the test batteries 選遞遞繭襯壓蓋衊遞築 (獵範齋憲壓廠觸壓構觸 ) 更多	积极	2015-11-04